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INTRODUCTION
People who inject drugs (PWID) were estimated to account for 51% of new human immunodeficiency virus (HIV-1) infections in Eastern Europe and central Asia in 2014, a region with the fastest growing HIV epidemic associated with injection drug use globally (UNAIDS, 2016; UNODC, 2016) .
Opioid injection has been the main driver of HIV epidemics in Estonia and the Russian Federation, where over half of PWID in Kohtla-Järve (Estonia) and St. Petersburg (Russian Federation) were seropositive in 2012 (El-Bassel, et al., 2013; Jolley, et al., 2012; Walsh, et al., 2013) . Both cities are situated on the Baltic Sea, on the northern part of two major heroin trafficking corridors linking Afghanistan to the heroin markets of Western Europe; both have experienced HIV epidemics driven by transmission among PWID since the late 1990s (UNODC, 2012 (UNODC, , 2015b . Despite similar HIV prevalence, estimated incidence was higher in Kohtla-Järve (22/100 person-years, 2012) than in St. Petersburg (7.2/100 person-years, 2010), partly due to the higher proportion of young PWID in the Estonian city and to differences in the context and epidemic response, presented in Table 1 . Evidence-based harm reduction interventions, including needle and syringe programmes (NSP) and opiate substitution treatment (OST), were introduced in Kohtla-Järve in 2004 (Estonia Ministry of Health, 2014 Mathers, et al., 2010) whereas in St Petersburg, OST remains illegal and clean needles and syringes are not endorsed by government and provided by a few nongovernmental organisations (Degenhardt, et al., 2014; EMCDDA, 2015) .
Most PWID injected heroin and illicitly-produced synthetic opioids, namely fentanyls in Kohtla-Järve (introduced into Estonia following a heroin shortage in 2000) and methadone in St Petersburg (Eritsyan, et al., 2013; Heimer, et al., 2015) . Estonia has reported one of the highest prevalences of amphetamine type stimulant (ATS) use in Europe (EMCDDA, et al., 2012; UNODC, 2014) and ATS have emerged as a major secondary drug among PWID in Kohtla-Järve and St. Petersburg (EMCDDA, 2010; Grund, et al., 2009; UNODC, 2015a) .
ATS are psycho-stimulants that are relatively easy to synthesize and increasingly injected in settings previously dominated by opiates (Bao, et al., 2012; Booth, et al., 2008; Grund, et al., 2009) . ATS have been associated with greater sexual risk, including multiple sex partners and unprotected sex, which may compound the risks of HIV acquisition among PWID (Baker, et al., 1994; Booth, et al., 2008; Darke, et al., 2008; Gleghorn, et al., 1998; Molitor, et al., 1999; Molitor, et al., 1998) . ATS injection has also been associated with more frequent injecting, needle/syringe sharing and HIV infection in settings where PWID also injected other drugs (Braine, et al., 2005; Hayashi, et al., 2011; Kozlov, et al., 2006; Tavitian-Exley, et al., 2017) but not when stimulants were reported as main injection drug (Booth, et al., 2008; Kral, et al., 1998; Swe, et al., 2012; Talu, et al., 2010) .
Few studies have examined drug use patterns by main drug injected and potential associations with risk behaviours and HIV and HCV infection in Eastern European settings (Booth, et al., 2008; Harrell, et al., 2012; Talu, et al., 2010; Tavitian-Exley, et al., 2015) and the relevance of ATS injection in shaping these epidemics remains unclear (EMCDDA, et al., 2011; EMCDDA, et al., 2014) .
Our aim is to assess whether primarily injecting ATS as compared to opioids (heroin, synthetic heroin or methadone) is associated with increased injecting and sexual risk behaviours and HIV status among PWID in Kohtla-Järve (Estonia) and St. Petersburg (Russian Federation), two East European locales with significant and epidemiologically similar HIV epidemics.
METHODS

Study population
Integrated biological and behavioural surveys of HIV prevalence were conducted among PWID in Kohtla-Järve between May and July 2012, and in St. Petersburg from November 2012 to June 2013. These surveys used comparable recruitment criteria and respondentdriven sampling (RDS) survey methodology and have been reported on and described previously (Cepeda, et al., 2015; Dukhovlinova, et al., 2015; Heimer, et al., 2015; Tavitian-Exley, et al., 2017; . Briefly, RDS starts with a diverse sample of seeds (6 seeds in Kohtla-Järve and 12 seeds in different districts of St.
Petersburg, subsequently increased to 16 to cover key districts and compensate for unproductive seeds). Seeds were selected through needle/syringe programmes (NSP) to represent a range of demographic and drug profiles; interviews and testing were conducted in fixed (Kohtla-Järve) and mobile clinics (St Petersburg). Each seed and subsequent participants were given an opportunity to recruit up to three PWID until a predetermined sample size was reached. Men and women aged 18 years or over, who had injected drugs in the past 30 days, lived in Kohtla-Järve or St. Petersburg and provided informed consent for the study were eligible. Eligibility was verified by the presence of injection marks and questions on injection practices before the start of the interview.
Measures
Information on demographic and social factors, injection and sexual risk behaviours and access to harm reduction services were recorded by trained fieldworkers in a structured confidential interviewer-administered questionnaire, using standardised study items and questions from established survey instruments (e.g. WHO Drug Injecting study Phase II survey v2b) .
HIV, HCV and HSV status
HIV sero-status was assessed using an HIV Antigen/Antibody Combo Assay (ADVIA Centaur, Siemens Healthcare Diagnostics) and HIV I/II Score line assay confirmatory test (INNO LIA, Fujirebio Europe) in Kohtla-Järve; rapid oral HIV testing was conducted in St.
Petersburg using OraQuick ADVANCE® Rapid HIV-1/2 Antibody Tests (OraSure Technologies Inc.) and confirmed at the City AIDS Centre . In Kohtla-Järve only, HCV and Herpes Simplex Virus (HSV) reactivity were measured using commercially available kits for antibodies to HCV (Murex anti-HCV v 4.0) and HSV-2 (HSV-2 IgG ELISA, IBL International GmbH).
The primary drug injected was categorised into mutually exclusive groups of primary ATS or primary opioid-injectors, based on the survey item main drug injected in the past 4 weeks. Injectors reporting no or "other" primary drug were compared with the rest of the sample and examined in descriptive analysis (and excluded in regression modelling).
Demographic and contextual variables
Demographic and contextual variables included age, sex, ethnicity, highest level of education completed (basic education/secondary and above), main source of income, living arrangements (stable/unstable), past month contact with an NSP, past year drug treatment (opioid substitution in Kohtla-Järve; any drug treatment in St. Petersburg) and having needles or syringes confiscated by the police.
Injecting and sexual risk behaviours
The behavioural variables examined included injecting-risk (using a 30 day recall period), sexual-risk behaviours (using a 6 month recall period) and serological markers for HIV (and in Kohtla-Järve only, HCV and HSV). Injecting behaviours of interest were past month injecting frequency (≥daily injecting vs. <daily injecting), intensity of injection on the last day injected (≥ 2 injections/day vs. <2 injections/day), injecting with used needles/syringes (sharing), sharing drug paraphernalia, back-loading (filling a syringe from a used syringe) and polydrug use (injecting a main drug and at least one other drug in the last month). Sexual risk behaviours included having a sex partner (regular or casual) who injected drugs, having been paid for sex (i.e. receiving money or drugs for sex ever), multiple sex partners (≥ 2 sex partners in last 6 months) and consistent condom use (i.e. always) with sex partners. The variable "any sex in the last six months" was used to exclude non-sexually active PWID.
Statistical analyses
Descriptive statistics are presented for Kohtla-Järve and St. Petersburg separately (RDSadjusted estimates, using the RDS-II estimator, are presented in supplementary material) (Volz, et al., 2008; Volz, et al., 2012; White, et al., 2015) .
Two sets of logistic regressions were performed. The first set examined the determinants of ATS-and opioid-injection. In the second set, we assessed whether ATS was associated with a) injecting-risk behaviours, b) sexual-risk behaviours, and c) HIV, HCV and HSV prevalence. For both sets of regressions, we generated univariate and multivariable estimates (Kirkwood, et al., 2003; UCLA Statistical Consulting Group, 2015) . Results for the multivariable regressions were adjusted for age, sex, education, living arrangements and duration of injecting. In the second set of regressions, we additionally adjusted for contact with NSP and drug treatment. These variables were judged to be important potential confounders, based on published evidence and our conceptual framework (Supplementary material: Figure S .1) (Lemstra, et al., 2012; Marshall, et al., 2008; Marshall, et al., 2011; Poundstone, et al., 2004; Tavitian-Exley, 2016) . Variables were examined for collinearity and omitted from the model if their variance inflation factor (VIF) was > 2.5. A complete case analysis was used and observations with missing values were omitted. Odds ratios (OR) with 95% confidence intervals (95%CI) were calculated while also adjusting for clustering of observations by recruitment seed (Kirkwood, et al., 2003) . Clusters were defined by a recruitment chain started by a given seed to account for the possibility that participants may be more likely to recruit other PWID with similar characteristics. This was achieved using the svy command in Stata (v.13.1) as in univariate analysis (Hosmer, 2000; Kirkwood, et al., 2003; StataCorp., 2013; UCLA Statistical Consulting Group, 2015) . Sampling weights were not taken into account in the regressions as their use is often unwarranted for causal inference (Solon, et al., 2013) .
Ethics
Ethical approval was obtained from the Ethics Review Board of the University of Tartu (Estonia), the Institutional Review Board at NGO Stellit in St. Petersburg (Russian Federation), and the Human Investigation Committee at Yale University (USA).
RESULTS
Characteristics of study sample
Our study included 591 PWID in Kohtla-Järve and 811 in St. Petersburg (Table 2; supplementary material Table S.1). In both cities, the majority of PWID were male, Russian-speaking or reporting stable living conditions (Table 2; Table S .1). However, more PWID in Kohtla-Järve were under the age of 30 and salaried or with a regular job than in St. Petersburg.
The primary drug commonly injected by PWID in both cities was a synthetic opioid (i.e. illicitly-manufactured fentanyl congeners in Kohtla-Järve, heroin and methadone produced in illicit laboratories in St. Petersburg) while ATS was the second most common drug class. Opioids were the primary drug for 61% of PWID in Kohtla-Järve and 96% in St. Petersburg; ATS was the main drug for 33% in Kohtla-Järve and 4% in St. Petersburg (6% of PWID in Kohtla-Järve had another or no primary drug).
More PWID had been in contact with a NSP in the past six months in Kohtla-Järve (82%) than in St. Petersburg (16%) and over half had ever received some form of attention for substance use disorder (Table 2) . Substitution treatment was reported by 13% of PWID in Kohtla-Järve and detoxification by 11% in St. Petersburg in the past 12 months. Similar proportions of PWID had needles/syringes confiscated by the police in the last six months in both cities, but more PWID reported ever being incarcerated in Kohtla-Järve (55%) than in St. Petersburg (34%).
The majority of PWID in both cities had injected for more than 5 years with a mean age at first injection of just under 19 years (Table S .1). Past-month injection risk behaviours were lower in Kohtla-Järve and up to nine times less frequent than in St. Petersburg. Pastmonth polydrug use (injection of main and other drug) was equally widespread in both cities (47% and 41%). Fewer PWID in Kohtla-Järve had injected at least daily (24%) than in St. Petersburg (36%), shared needles and syringes (6% and 58%), filled from a used syringe (6% and 53%) or shared drug paraphernalia (7% and 68%).
Over three quarters of PWID in both cities had had sexual intercourse in the last 6 months and over half had a sex partner who injected drugs (55% in Kohtla-Järve and 58% in St. Petersburg). Over a third of PWID had multiple sex partners (34% and 49%) and 7% in Kohtla-Järve and 4% in St. Petersburg respectively had ever been paid for sex. Close to half of PWID always used condoms with casual partners in Kohtla-Järve (58%) and St.
Petersburg (48%). Due to the high non-response rate (>50%) for some sexual risk behaviours in Kohtla-Järve, results for this city were not shown, given the high likelihood of bias; we only analysed the effect of ATS-or opioid-injection for those variables in St.
Petersburg (Table S .1). More than half of PWID tested positive for HIV in Kohtla-Järve (61%) and in St. Petersburg (56%). HCV and HSV reactivity measured in Kohtla-Järve only, was 75% and 32%, respectively.
Associations between primary ATS injection and injecting and sexual risk behaviours and serology in Kohtla-Järve
Determinants of ATS injection
Determinants of primary ATS injection are presented in Table 3 . In Kohtla-Järve, ATS injectors were younger than opioid injectors with greater odds of being under 30 years of age (adjusted Odds Ratio (aOR) =2.1; 95%CI: 1.4-3.2) and of later injection initiation (aOR: 1.1; 95%CI: 1.0-1.4) than their opioid-injecting peers. The groups did not differ on other demographic characteristics. ATS injectors had lower odds of past-year drug treatment (aOR=0.5; 95%CI: 0.3-0.9), past-month contact with an NSP (aOR=0.2; 95%CI: 0.2-0.6), having needles/syringes confiscated by the police (aOR=0.3; 95%CI: 0.1-0.8) and incarceration (aOR=0.3; 95%CI: 0.2-0.5). They had higher odds of obtaining clean needles/syringes from a pharmacy than an NSP (aOR: 4.9 (95%CI: 3.5-6.9).
Associations with injecting risk behaviours
Primary ATS injection was associated with a number of injecting risk behaviours (Table   4 ). ATS injectors were more likely to have injected for less than 5 years (aOR=3.5; 95% CI: 1.9-6.2) ( Table 4 ). ATS injection was negatively associated with frequent injecting (aOR=0.3; 95%CI: 0.2-0.6), lifetime needle/syringe-sharing (aOR= 0.3; 95%CI: 0.2-0.5) and back-loading (aOR= 0.4; 95%CI: 0.2-0.8) and was positively associated with polydrug use (aOR=2.0; 95%CI: 1.1-3.5). Past-month unsafe sharing practices such as sharing needles/syringe and drug paraphernalia were generally lower among primary ATS injectors but differences did not reach statistical significance (Table 4) .
Associations with sexual risk behaviours
One third of PWID reported multiple sex partners with no significant difference between primary ATS-and opioid-injectors; however ATS injectors had greater odds of ever being paid for sex (aOR=2.6; 95%CI: 1.2-5.7)( Table 5) .
Associations with HIV, HCV and HSV prevalence
Primary ATS injectors in Kohtla-Järve had lower odds of testing positive for HIV (aOR=0.6; 95%CI: 0.5-0.8) and having antibodies to HCV (aOR=0.5; 95%CI: 0.3-0.6) in multivariate analysis, compared to primary opioid injectors (Table 6 ). HSV antibody status was not associated with ATS injection.
Associations between primary ATS injection and injecting and sexual risk behaviours and HIV in St. Petersburg
Determinants of ATS injection
In St. Petersburg, primary ATS injectors had higher odds of being under 30 years of age (aOR=6.8; 95%CI: 2.8-16.5), female (aOR=1.7; 95%CI: 0.7-4.1), of later initiation to injection (aOR: 1.3; 95%CI: 1.1-1.4) or having unstable living arrangements (aOR=2.2; 95%CI: 1.0-4.6) than opioid injectors (Table 3) . Contact with NSP and drug treatment were very low in St. Petersburg and did not differ between ATS-and opioid-injectors.
However ATS injectors had greater odds of obtaining needles and syringes from sources other than an NSP (e.g. from friends, other PWID, a drug dealer or in the street) (aOR=35; 95%CI: 2.7-472) and lower odds of having been incarcerated and having needles/syringes confiscated compared to opioid injectors.
Associations with injecting risk behaviours
Primary ATS injectors were more likely to report fewer than 5 years of injecting (aOR=8.3; 95%CI: 2.2-31.6)( Table 4 ). Several injecting risk behaviours were negatively associated with ATS injection. Primary ATS injectors had lower odds of daily or more frequent injecting (aOR=0.2; 95%CI: 0.1-0.9), injecting more than twice a day (aOR: 0.3; 95%CI: 0.1-0.6), sharing needles and syringes (aOR=0.2; 95%CI: 0.1-0.6), filling a syringe from a used syringe (aOR=0.2; 95%CI: 0.1-0.5) and sharing drug paraphernalia (aOR=0.3; 95%CI: 0.1-0.6) than opioid injectors. Polydrug use was frequent among both ATS-and opioid-injectors but did not differ significantly between the two groups.
Associations with sexual risk behaviours
Almost half of PWID in the Russian city reported multiple sex partners, with no significant difference between ATS-and opioid-injectors (Table 5 ). In multivariate analysis, ATS injectors had greater odds of being paid for sex (aOR=5.2; 95%CI: 1.0-27.0) and using condoms consistently with casual sex partners (aOR=8.0; 95%CI: 1.1-60.0).
Associations with HIV prevalence
Primary ATS injectors in St. Petersburg had lower odds of testing positive for HIV than PWID injecting opioid (aOR=0.3; 95%CI: 0.1-0.7) (Table 6 ). HCV and HSV serology were not collected in St. Petersburg.
DISCUSSION
We compared risk behaviours and HIV status among self-identified primary ATSinjectors and opioid-injectors in two settings with severe epidemics of drug use and HIV.
Our results suggest that, in both locations, PWID primarily injecting ATS consistently differed on demographic characteristics and reported less or equally risky injecting behaviours compared to those who mainly injected opioids. ATS injectors in both cities were younger but started injecting later than opiate injectors, were more likely to report less than 5 years' injecting and generally at earlier stages in their drug injecting careers.
The younger age and later onset of injecting among ATS injectors, suggested the emergence of a different group of PWID who may be at earlier stages of drug dependence and injecting less frequently than their opioid-injecting peers.
In St. Petersburg, contact with NSPs was generally low and did not differ between the two groups; there primary ATS injectors were less likely to have injected with used needles/syringes, shared drug paraphernalia or back-loaded than opiate injectors.
However in Kohtla-Järve, where harm reduction services are established, ATS injectors were significantly less likely than opiate injectors to have had contact with NSPs and reported similar prevalence of sharing needles/syringes or drug paraphernalia. They were also less likely to back-load than opiate injectors. That more opiate injectors were in contact with NSPs (and OST) in Kohtla-Järve may have contributed to reducing risky injecting behaviours in this group, thus "levelling" injecting risk between the two drug groups.
Our findings are generally consistent with other studies, where self-reported primary ATS injection was associated with younger age and fewer years of injecting among PWID in Australia (Kaye, et al., 2000) , the USA (Braine, et al., 2005) , Canada (Fairbairn, et al., 2007) , Ukraine and elsewhere in Estonia (Booth, et al., 2008; Talu, et al., 2010) and where primary ATS injectors reported similar or lower frequency of injection (Booth, et al., 2008; Braine, et al., 2005; Darke, et al., 2008; Gleghorn, et al., 1998; Kaye, et al., 2000; Maher, et al., 2007; Talu, et al., 2010) and similar frequency of needle and syringesharing than opiate injectors (Gleghorn, et al., 1998; Kaye, et al., 2000; Talu, et al., 2010) .
That primary ATS injectors in our study reported lower or similar injecting risk behaviours than opiate injectors contrasts with findings from studies where ATS injection was not defined as main drug and occurred in the presence of other injection drugs, including heroin (Braine, et al., 2005; Crofts, et al., 1997; Hayashi, et al., 2011; Kozlov, et al., 2006; Martin, et al., 2010; Tavitian-Exley, et al., 2017) . Injecting risk behaviours and infection risk associated with ATS injection may therefore differ depending on whether PWID inject ATS primarily or inject ATS in addition to or in combination with, addictive opiates such as heroin; these underline the need for consistent definitions and regular monitoring of drugs and drug combinations among PWID.
Both ATS-injectors and opioid-injectors in this study reported similarly high prevalence of sexual risk, including multiple sex partners. However primary ATS injectors were more likely to have ever been paid for sex. ATS may be used to increase energy, stamina, libido and to reduce social and sexual inhibition. Further, injection often occurs with peers or sexual partners, possibly generating more needle-sharing opportunities (Darke, et al., 1995; Klee, 1993) . Several other studies of PWID also found positive associations between ATS injection and multiple sex partners, unprotected sex and trading sex for money or drugs (Lorvick, et al., 2006; Molitor, et al., 1999) . The frequency of sexual risk in both cities and possible intersection with sex work highlight the potential for sexual transmission of HIV, and an unmet need to engage diverse PWID sub-groups with prevention and risk reduction messages emphasising sexual as well as injecting risks (Lorvick, et al., 2006; Molitor, et al., 1998; Rondinelli, et al., 2009 ).
Finally, HIV prevalence and HCV in Kohtla-Järve; were lower among ATS-than opioidinjectors, consistent with their shorter, cumulative exposure to risk resulting from younger age and later onset of injecting (Kozlov, et al., 2006; Martin, et al., 2010) . These differences in HIV status remained after adjusting for factors such as injecting duration, suggesting that other determinants also play a role. Primary ATS injectors are nevertheless vulnerable to HIV acquisition as a result of their age (and gender in St. Petersburg), high prevalence of sexual risk behaviours and low contact with harm reduction services (i.e. NSP and drug substitution treatment in Kohtla-Järve).
The propensity of ATS injectors in Kohtla-Järve to obtain clean needles and syringes from pharmacies rather than NSPs when the majority of PWID in the sample were in contact with harm reduction services, also suggests they were not being reached (Vorobjov, et al., 2009 ). Furthermore, the lower odds of substitution treatment among ATS injectors in Kohtla-Järve may be expected since methadone-based substitution treatment has shown to reduce injecting risk behaviours and HIV infection and to support adherence to highly active anti-retroviral therapy (HAART) among opioid users. However no proven pharmacological treatment exists for ATS-dependent injectors (Ahamad, et al., 2015; MacArthur, et al., 2012; World Health Organization, 2013) . Where ATS use is prevalent, services that are tailored to the demographic characteristics and specific needs of ATS injectors and include psychosocial interventions, need to be integrated into harm reduction programmes (Mehrjerdi, et al., 2014; UNODC, 2010) . The problem of ATS injection in these cities, and globally, requires effective low-threshold services able to engage injectors who are young and/or female, do not fit the drug use "profile" associated with heroin and neither seek nor desire contact with services focused on opioid injectors (Lorvick, et al., 2006; Pates, 2013; Shearer, et al., 2002; Vorobjov, et al., 2009 ).
Moreover, while few studies have looked at the life course of drug use among primary ATS injectors, especially in resource-limited settings (Brecht, et al., 2008) Several limitations need to be acknowledged. First, our findings may only be generalizable to other PWID populations in Estonia or the Russian Federation. Second, obtaining standard probability samples of PWID populations is challenging, due to the hidden nature of this group, their stigmatised behaviours and the absence of a sampling frame. Although RDS surveys have demonstrated the ability to reach hidden population sub-groups, the representativeness of our samples cannot be verified (Abdul-Quader, et al., 2006; Heckathorn, 1997; Johnston, et al., 2010) . Third, information on injecting and sexual risk behaviours was collected through self-reports and social desirability bias may affect the results. Self-reporting using interviewer-administered questionnaires has shown reliability in several studies and a 30-day period, as was used in this study, has shown to produce reliable recall on drug use and injecting behaviours among PWID (Darke, 1998; Des Jarlais, et al., 1999; Napper, et al., 2010) . Additionally, the small number of ATS injectors in St. Petersburg resulted in wide confidence intervals that limited our analyses for this city. Finally, given the dynamic nature of drug use, high prevalence of polydrug use in this population and shorter recall, it is conceivable that misclassification may have occurred between ATS-and opioid-injectors thus leading to possible bias. However, nondifferential misclassification of the exposure generally biased the inferences towards the null and, if this is the case here, our results could be considered conservative (Dosemeci, et al., 1990; Kirkwood, et al., 2003) .
The strengths of this study include its large sample size and comparisons of two Eastern
European locations reporting a high prevalence of HIV and injection of different drug classes. Recruitment of two large and diverse PWID samples was facilitated by the use of RDS and reported according to the STROBE-RDS statement (Johnston, et al., 2016; White, et al., 2015) . We systematically compared PWID injecting different drug classes, using consistent definitions, study methods and tested tools and we highlighted important differences between self-identified primary ATS-and opioid-injectors that are of relevance to policy and programmes.
Primary ATS injectors reported lower or similar injecting risk behaviours, lower HIV prevalence and less engagement with services, than opioid injectors. Both groups had high levels of multiple sex partners but primary ATS injection was associated with paid sex, suggesting overlaps between injecting and sexual risk. Low threshold interventions (e.g. behavioural) and supplies targeting the needs of young stimulant injectors are needed to increase their contact with prevention services and reduce sexual risk behaviours. The coverage of harm reduction services, including sexual risk reduction, needs to be increased significantly in St. Petersburg for all PWID.
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